STOCK TITAN
  1. Home
  2. News
  3. BMY

Bristol-Myers Squibb Co - BMY STOCK NEWS

Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.

Bristol-Myers Squibb Co. (BMY) is a renowned American multinational pharmaceutical company headquartered in New York City. As one of the largest pharmaceutical companies globally, Bristol-Myers Squibb (BMS) consistently ranks on the Fortune 500 list. In fiscal 2022, the company achieved total revenue of $46.2 billion.

Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs across various therapeutic areas, including cardiovascular, cancer, and immune disorders. A significant area of focus for BMS is immuno-oncology, where it has established itself as a leader in drug development. Approximately 70% of BMS's total sales are derived from the U.S. market, reflecting its higher dependence on this region compared to its peers.

Recent achievements and collaborations highlight BMS's commitment to innovation and partnerships. On May 22, 2024, BMS joined NeoPhore Limited's oversubscribed Series B extension round. This additional investment will enable NeoPhore to explore novel biology associated with the DNA mismatch repair (MMR) pathway in cancer, and further advance its pre-clinical studies. NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients.

Another noteworthy collaboration was announced on June 5, 2024, with I-Mab, a U.S.-based global biotech company. This partnership will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody, with BMS's immune checkpoint inhibitor, nivolumab, and chemotherapy. The study, a multi-national Phase 1, will focus on advanced Claudin 18.2-positive gastric and esophageal cancers. BMS will supply nivolumab, which is designed to enhance T-cell function and improve anti-tumor responses.

Additionally, on June 5, 2024, Envisagenics, an AI-driven biotechnology company, announced a Series B fundraising round with participation from BMS. This funding will be utilized to further develop Envisagenics' pipeline of novel preclinical oncology assets using their cloud-based AI drug discovery platform, SpliceCore®. This collaboration underscores BMS's continued investment in innovative technologies and therapeutics.

Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. Through strategic partnerships, cutting-edge research, and a commitment to therapeutic advancements, BMS continues to make significant strides in the biopharmaceutical industry.

News

Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

Rhea-AI Summary
Bristol Myers Squibb (BMY) announced updated results from the registrational TRIDENT-1 study, demonstrating high response rates and durable responses in patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer. The study also showed intracranial activity and promising results among patients who were previously treated with one TKI and no chemotherapy. The U.S. FDA accepted the New Drug Application for repotrectinib, and the drug is under Priority Review. Median duration of response and progression-free survival will be disclosed for the first time at the IASLC 2023 World Conference on Lung Cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
none
-
News

Viz.ai Receives First De Novo Approval by the FDA for Hypertrophic Cardiomyopathy AI Algorithm

Rhea-AI Summary
Viz.ai has received FDA approval for its Viz HCM module, an AI detection algorithm for hypertrophic cardiomyopathy (HCM). The algorithm is financially supported by a multi-year agreement with Bristol Myers Squibb. Viz HCM can identify suspected HCM cases earlier using AI, allowing for prompt diagnosis and evaluation. The algorithm automatically reviews electrocardiograms (ECGs) to identify cases and notifies cardiologists. Viz.ai's platform has been shown to improve patient outcomes in over 1,400 hospitals. This FDA approval establishes a new category for cardiovascular machine learning-based notification software.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
AI
-
News

Bristol Myers Squibb Enters Into $4 Billion Aggregate Accelerated Share Repurchase Agreements

Rhea-AI Summary
Bristol Myers Squibb (BMY) announces $4 billion accelerated share repurchase program, expecting to fund the repurchases with cash on-hand. Approximately 85 percent of the shares to be repurchased will be received by Bristol Myers Squibb on August 10, 2023. The total number of shares ultimately repurchased will be determined upon final settlement and will be based on a discount to the volume-weighted average price of Bristol Myers Squibb’s common stock during the terms of the ASR transactions. The ASR transactions are expected to be settled during the fourth quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
buyback
News

Bristol Myers Squibb Launches Clear Understanding Campaign to Reveal the Plain Truth About Living with Moderate to Severe Plaque Psoriasis

Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) Launches Clear Understanding Campaign to Support Patients with Moderate to Severe Plaque Psoriasis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
none
-
News

Bristol Myers Squibb Reports Second Quarter Financial Results for 2023

Rhea-AI Summary
Bristol Myers Squibb (BMY) reports Q2 2023 revenues of $11.2 billion, GAAP EPS of $0.99 and Non-GAAP EPS of $1.75. The company revises outlook for total revenues to low single-digit decline, GAAP EPS to $3.72-$4.02, and Non-GAAP EPS to $7.35-$7.65 due to lower expected revenues for Revlimid and Pomalyst. Announces $4 billion accelerated share repurchase agreement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.23%
Tags
earnings
-
News

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

Rhea-AI Summary
Bristol Myers Squibb (BMY) receives CHMP recommendation for Opdivo (nivolumab) as a monotherapy for the adjuvant treatment of adults and adolescents 12 years of age and older with completely resected stage IIB or IIC melanoma. Opdivo demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival versus placebo in the Phase 3 CheckMate -76K trial. If approved, Opdivo would become the only PD-1 inhibitor indicated as an adjuvant treatment for patients within stages IIB, IIC, III, as well as stage IV resected melanoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
none
News

Bristol Myers Squibb Launches Supporting You with UC, with Women’s World Cup Commentator, Former Professional Soccer Player and Ulcerative Colitis Patient, Rosie White

Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) launches 'Supporting You with UC' campaign with patient ambassador Rosie White, providing practical resources for managing ulcerative colitis (UC) symptoms. Approximately 600,000 to 900,000 people in the US live with UC, a chronic, immune-mediated inflammatory bowel disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
none
-
News

Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
clinical trial
-
News

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression ≥1%

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
none
News

K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Translocation (4;14)

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
none

FAQ

What is the current stock price of Bristol-Myers Squibb Co (BMY)?

The current stock price of Bristol-Myers Squibb Co (BMY) is $57.88 as of February 24, 2025.

What is the market cap of Bristol-Myers Squibb Co (BMY)?

The market cap of Bristol-Myers Squibb Co (BMY) is approximately 116.2B.

What is Bristol-Myers Squibb's core business?

Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs for various therapeutic areas, including cardiovascular, cancer, and immune disorders.

Where is Bristol-Myers Squibb headquartered?

Bristol-Myers Squibb is headquartered in New York City, USA.

What was Bristol-Myers Squibb's revenue for fiscal 2022?

Bristol-Myers Squibb reported a total revenue of $46.2 billion for fiscal 2022.

What is a significant focus area for Bristol-Myers Squibb?

A significant focus area for Bristol-Myers Squibb is immuno-oncology, where it is a leader in drug development.

How much of Bristol-Myers Squibb's total sales come from the U.S. market?

Approximately 70% of Bristol-Myers Squibb's total sales are derived from the U.S. market.

What recent collaboration did Bristol-Myers Squibb announce with NeoPhore Limited?

On May 22, 2024, Bristol-Myers Squibb joined NeoPhore Limited's Series B extension round to explore novel biology associated with the DNA mismatch repair pathway in cancer.

What is the purpose of Bristol-Myers Squibb's collaboration with I-Mab?

The collaboration with I-Mab focuses on evaluating the combination of givastomig with BMS's nivolumab and chemotherapy for advanced Claudin 18.2-positive gastric and esophageal cancers.

What is SpliceCore®?

SpliceCore® is Envisagenics' cloud-based AI drug discovery platform that integrates machine learning algorithms to identify novel and disease-specific RNA splicing isoforms.

When did Bristol-Myers Squibb participate in Envisagenics' Series B fundraising round?

Bristol-Myers Squibb participated in Envisagenics' Series B fundraising round announced on June 5, 2024.

What is Bristol-Myers Squibb's mission?

Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.
Stock BMY logo
Bristol-Myers Squibb Co

NYSE:BMY

BMY Rankings

#96 Ranked by Market Cap
#720 Ranked by Dividends

BMY Stock Data

116.18B
2.02B
0.12%
78.52%
1.36%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
PRINCETON